To view this email as a web page, click here.
New Pathways and Chemotherapeutic
Delivery Mechanisms in the Treatment of
Metastatic Breast Cancer
 
December 17 • 3:00 PM & 5:00 PM
 
 
Metastatic breast cancer (mBC) remains the leading cause of cancer-related death in women. Chemotherapy remains the backbone of mBC treatment; however, new developments across the therapeutic spectrum are expanding clinical approaches to care. Among chemotherapy agents, efforts are underway to improve delivery mechanisms, efficacy, and toxicity profiles, with a shift towards oral therapy, but how do we balance value, costs and health improvements?
 
In this webinar, gain insights from leaders from West Cancer Center and Stanford Cancer as they discuss the shifting treatment paradigm in mBC and their approach to ensuring success with oral therapy.
 
 
Meet the Experts
 
Moderator
Adam M. Brufsky, MD, PhD, FACP
Professor of Medicine
University of Pittsburgh School of Medicine		 Panel
Lee Schwartzberg, MD, FACP
Chief Medical Officer West Cancer Center		 Panel
George W. Sledge Jr., MD
Medical Oncologist, Breast Specialist Stanford Cancer Center
 
 

Learning Objectives:
  • Explore unmet treatment needs and innovations in metastatic breast cancer, particularly the developing spectrum of chemotherapeutic interventions
  • Educate oncology community on emerging therapies in mBC with an emphasis on oral therapy
  • Discuss benefits and challenges of oral therapy, including the impact of COVID-19 on uptake
 
 

Join us as we discuss new pathways and chemotherapeutic delivery mechanisms in the treatment of metastatic breast cancer.
We look forward to seeing you on December 17th.

 
This email was sent by: %%Member_Busname%%
%%Member_Addr%%, %%Member_City%%, %%Member_State%%, %%Member_PostalCode%% %%Member_Country%%

Privacy Policy

Update Profile      Manage Subscriptions      Unsubscribe